Comparison of aclidinium bromide and formoterol fumarate in patients with moderate to severe Chronic obstructive pulmonary disease (COPD)

Study identifier:LAC-MD-24

ClinicalTrials.gov identifier:NCT00706914

EudraCT identifier:N/A

CTIS identifier:N/A

Terminated/Withdrawn

Official Title

A Randomized, Double-Blind, Active-Controlled, Parallel-Group, Multicenter, 4-Week Pilot Study to Assess Symptoms in Stable, Moderate to Severe COPD Patients Taking Aclidinium Bromide 200 mcg Once Daily in Combination With Formoterol Fumarate Once or Twice Daily Versus Formoterol Fumarate Twice Daily

Medical condition

Pulmonary Disease, Chronic Obstructive

Phase

Phase 2

Healthy volunteers

No

Study drug

Once-daily aclidinium/formoterol, Twice-daily formoterol fumarate, Placebo to formoterol fumarate, Once-daily formoterol fumarate

Sex

All

Actual Enrollment

156

Study type

Interventional

Age

40 Years - 80 Years

Date

Study Start Date: 30 Jun 2008
Primary Completion Date: 11 Nov 2008
Study Completion Date: 11 Nov 2008

Study design

Allocation: Randomized
Endpoint Classification: Safety/Efficacy
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment

Verification:

Verified 01 Apr 2017 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria